CXCL13 and neoplasm: Extending DDS-IH to cancer immunotherapy, Kuwentrai et al. [66] studied an injectable hydrogel-based drug formulation that enhances the efficacy of cancer immunotherapy and stimulates the formation of tertiary lymphoid structures (TLSs) that recruit B and T cells and promote mature TLS formation in the tumor microenvironment through localized co-delivery of the immunomodulatory proteins CXCL13 and LIGHT proteins.